Mechanism of hypoxia mediated radiation lung injury
Mechanism of hypoxia mediated radiation lung injury
批准号:
6683011
负责人:
ZELJKO VUJASKOVIC
金额:
$27.17万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-08-01 至 2007-07-31
关键词:
biomimetics blood vessels cardiovascular injury disease /disorder prevention /control electron spin resonance spectroscopy enzyme activity free radical oxygen gadolinium immunocytochemistry laboratory rat leukocyte activation /transformation lung injury lung ischemia /hypoxia macrophage metalloporphyrins neoplasm /cancer radiation therapy nonhuman therapy evaluation oxygen consumption pathologic process pulmonary circulation radiobiology superoxide dismutase therapy adverse effect transforming growth factors vascular endothelial growth factors
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The risk of unacceptable radiation (RT)-induced lung injury remains a significant limiting factor in the current treatment of the tumors involving the thoracic region. Despite advances in normal tissue radiobiology demonstrating that ionizing radiation triggers a cascade of genetic and molecular events, which lead to pulmonary injury, it is still unclear how a prolonged response to injury can be sustained for months to years after irradiation has ended. This deficiency in understanding of the mechanisms of RT-induced lung injury has hindered the development of appropriate interventional approaches to prevent this serious problem. The current proposal is based on our recent finding implicating hypoxia as an important contributing factor in the development of RT-induced pulmonary injury. We believe that hypoxia results from two factors: 1) increased oxygen consumption by activated macrophages with associated production of reactive oxygen species (ROS) and cytokines, and 2) decreased oxygen delivery to tissue due to vascular damage causing reduced perfusion. We hypothesize that hypoxia mediates a cycle of continuous, macrophage-associated production of ROS and expression/activation of profibroqenic and proanqioqenic cytokines. This process leads to l disre.qulation of angiogenesis, endothelial cell death, and collagen deposition which result in sustained hypoxia that I_erpetuates further pulmonary tissue damage and fibrosis, The goal of this study is to determine the I temporal onset of hypoxia after lung irradiation, and to define how hypoxia relates to macrophage activity (the production of ROS and cytokines) and vascular damage at different time points after irradiation. Lung hypoxia will be determined using the EF5 hypoxia marker. Macrophage activation will be assessed by immunohistochemistry. ROS will be detected using electron spin resonance (ESR) spectroscopy and spin trapping. A radionuclide perfusion assay will be used to assess pulmonary perfusion. After characterizing the relationship between hypoxia, macrophage activation and vascular damage following RT we will attempt to disrupt this injury cycle in two ways. First, ROS will be targeted directly with superoxide dismutase (SOD) mimetics. Second, ROS mediated injury will be targeted indirectly by inhibiting macrophage activity with gadolinium chloride (GdCI3). If successful, this project may lead directly to the development of clinically applicable strategies to reduce the risk of RT-induced lung injury in an attempt to permit delivery of higher doses of radiation to thoracic tumors without increasing the risk of pulmonary complications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mitigation of Radiation-Induced Pulmonary Injury with Nrf2 activator
-
批准号:8573174
-
项目类别:
-
资助金额:$53.46万
-
财政年份:2013
-
负责人:ZELJKO VUJASKOVIC
-
依托单位:
Mitigation of Radiation-Induced Pulmonary Injury with Nrf2 activator
-
批准号:8830429
-
项目类别:
-
资助金额:$67.12万
-
财政年份:2013
-
负责人:ZELJKO VUJASKOVIC
-
依托单位:
Mitigation of Radiation-Induced Pulmonary Injury with Nrf2 activator
-
批准号:9264491
-
项目类别:
-
资助金额:$52.12万
-
财政年份:2013
-
负责人:ZELJKO VUJASKOVIC
-
依托单位:
Mitigation of Radiation-Induced Pulmonary Injury with Nrf2 activator
-
批准号:8660639
-
项目类别:
-
资助金额:$67.36万
-
财政年份:2013
-
负责人:ZELJKO VUJASKOVIC
-
依托单位:
Radiation Protection with SOD Mimetics
-
批准号:8306950
-
项目类别:
-
资助金额:$26.85万
-
财政年份:2011
-
负责人:ZELJKO VUJASKOVIC
-
依托单位:
Radiation Protection with SOD Mimetics
-
批准号:8013118
-
项目类别:
-
资助金额:$25.47万
-
财政年份:2010
-
负责人:ZELJKO VUJASKOVIC
-
依托单位:
Antioxidant Mimetic as a Mitigator of Radiation Induced Lung Injury
-
批准号:7586542
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2010
-
负责人:ZELJKO VUJASKOVIC
-
依托单位:
MECHANISM OF RADIATION-INDUCED LUNG INJURY
-
批准号:7601181
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2007
-
负责人:ZELJKO VUJASKOVIC
-
依托单位:
SPATIAL DISTRIBUTION OF PULMONARY FUNCTION OF THE RAT LUNG
-
批准号:7601157
-
项目类别:
-
资助金额:$1.0万
-
财政年份:2007
-
负责人:ZELJKO VUJASKOVIC
-
依托单位:
SPATIAL DISTRIBUTION OF PULMONARY FUNCTION OF THE RAT LUNG
-
批准号:7358307
-
项目类别:
-
资助金额:$0.51万
-
财政年份:2006
-
负责人:ZELJKO VUJASKOVIC
-
依托单位:
MRI ASSESSMENT OF LUNG PERFUSION AFTER RADIATION
-
批准号:7358278
-
项目类别:
-
资助金额:$1.54万
-
财政年份:2006
-
负责人:ZELJKO VUJASKOVIC
-
依托单位:
MRI ASSESSMENT OF LUNG PERFUSION AFTER RADIATION
-
批准号:7181552
-
项目类别:
-
资助金额:$1.6万
-
财政年份:2005
-
负责人:ZELJKO VUJASKOVIC
-
依托单位:
TISSUE
-
批准号:7006351
-
项目类别:
-
资助金额:$12.86万
-
财政年份:2005
-
负责人:ZELJKO VUJASKOVIC
-
依托单位:
Radiation protection with SOD mimetics
-
批准号:7052921
-
项目类别:
-
资助金额:$22.35万
-
财政年份:2005
-
负责人:ZELJKO VUJASKOVIC
-
依托单位:
HP GAS IMAGING IN RADIATION INDUCED PNEUMONITIS
-
批准号:6977804
-
项目类别:
-
资助金额:$4.19万
-
财政年份:2004
-
负责人:ZELJKO VUJASKOVIC
-
依托单位:
MRI ASSESSMENT OF LUNG PERFUSION AFTER RADIATION
-
批准号:6977869
-
项目类别:
-
资助金额:$0.7万
-
财政年份:2004
-
负责人:ZELJKO VUJASKOVIC
-
依托单位:
Mechanism of hypoxia mediated radiation lung injury
-
批准号:7095903
-
项目类别:
-
资助金额:$26.14万
-
财政年份:2003
-
负责人:ZELJKO VUJASKOVIC
-
依托单位:
Mechanism of hypoxia mediated radiation lung injury
-
批准号:6927207
-
项目类别:
-
资助金额:$27.41万
-
财政年份:2003
-
负责人:ZELJKO VUJASKOVIC
-
依托单位:
Mechanism of hypoxia mediated radiation lung injury
-
批准号:6776912
-
项目类别:
-
资助金额:$27.41万
-
财政年份:2003
-
负责人:ZELJKO VUJASKOVIC
-
依托单位:
Radiation protection with SOD mimetics
-
批准号:7310442
-
项目类别:
-
资助金额:$22.69万
-
财政年份:--
-
负责人:ZELJKO VUJASKOVIC
-
依托单位:
海外基金